89bio announces additional data from the enliven phase 2b trial of pegozafermin in patients with compensated cirrhotic (f4) nonalcoholic steatohepatitis (nash) at aasld the liver meeting® 2023

—reductions in key non-invasive tests (nits) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (f4) patients at week 24—
ETNB Ratings Summary
ETNB Quant Ranking